Trial Profile
A phase 2 multicenter study evaluating the safety and efficacy of Nilotinib in patients with Imatinib-resistant/intolerant Ph+CML in chronic phase
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2015
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Myeloid leukaemia
- Focus Therapeutic Use
- 29 Dec 2012 New trial record